4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …

Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of
worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We …

Background: DANISH (The Danish Study to Assess the Efficacy of Implantable Cardioverter
Defibrillators [ICDs] in Patients With Nonischemic Systolic Heart Failure on Mortality) found …

Aims Risk stratification algorithms for sudden cardiac death (SCD) in hypertrophic
cardiomyopathy (HCM) and regional differences in clinical practice have evolved over time …

Sudden death is a devastating complication of heart failure (HF). Current guidelines
recommend an implantable cardioverter‐defibrillator (ICD) for prevention of sudden death in …

The impact of sudden cardiac death (SCD) in heart failure (HF) patients is important and
prevention of SCD is a reasonable and clinically justified endpoint if associated with a …

Aims Use of implantable cardioverter‐defibrillators (ICD) for primary prevention of sudden
cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We …

Aims Differences between female and male patients in clinical presentation, causes and
treatment of cardiogenic shock (CS) are poorly understood. We aimed to investigate sex …

Aims Randomized data on the efficacy/safety of cardiac resynchronization therapy with vs.
without defibrillator (CRT-D,-P) in heart failure with reduced ejection fraction (HFrEF) are …